Amgen Inc
AMGNHealthcare|Drug Manufacturers - General|USA
$342.57
-5.37 (-1.54%)
DCF (FCF)
$219.78
Earnings Power
$83.10
Upcoming Data Readouts (41)
Jul 2026
Est. completion
P3Eosinophilic Esophagitis
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05583227n=368
Aug 2026
Est. completion
P3Sjogren's Syndrome
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
NCT06104124n=651
Oct 2026
Est. completion
P1Prostate Cancer
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
NCT06555796n=50
Dec 2026
Est. completion
P2Relapsed/Refractory Small Cell Lung Cancer
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016n=222
Dec 2026
Est. completion
Jan 2027
Est. completion
Feb 2027
Est. completion
P1P2Thyroid Eye Disease
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
NCT06401044n=88
Mar 2027
Est. completion
P2Premenopausal Idiopathic Osteoporosis
Romosozumab/Denosumab Study for Premenopausal IOP
NCT04800367n=30
May 2027
Est. completion
P4Glucocorticoid-induced Osteoporosis
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
NCT06588153n=100
Jun 2027
Est. completion
P1Asthma
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
NCT06637371n=124
Jun 2027
Est. completion
P3Atopic Dermatitis
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05882877n=2,621
Sep 2027
Est. completion
Sep 2027
Est. completion
P3Obstructive Sleep Apnea
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
NCT07226765n=250
Jan 2028
Est. completion
Jan 2028
Est. completion
P2Systemic Lupus Erythematosus
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798n=220
Mar 2028
Est. completion
P1Extensive Stage Small Cell Lung Cancer
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
NCT07037758n=380
Mar 2028
Est. completion
P3Active Juvenile Psoriatic Arthritis
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
NCT04804553n=60
Apr 2028
Est. completion
P2DLL3-expressing Tumors
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
NCT06788938n=29
May 2028
Est. completion
P3Uncontrolled Gout
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout
NCT07388498n=270
Jun 2028
Est. completion
P3Heart Failure With Preserved Ejection Fraction
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459n=5,056
Awaiting Results (22)
Trials past primary completion date but still active — data readout may be imminent.
Jun 2026
P1P2
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810May 2026
P1P2
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
NCT05094336May 2026
P1
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT06131398May 2026
P3
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
NCT03937154Mar 2026
P2
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
NCT06312020Mar 2026
P2
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
NCT04329325Jan 2026
P2
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113Dec 2025
P1
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
NCT02332850Nov 2025
P1P2
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
NCT05322577Nov 2025
P3
A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
NCT05565560